PIK3CA in HCC — no targeted approval; atezolizumab + bevacizumab / lenvatinib per usual a...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PIK3CA-HOTSPOT-HCC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-HCC |
| Sources | SRC-CIVIC SRC-NCCN-HCC-2025 |
Actionability Facts
| Biomarker | BIO-PIK3CA-MUTATION |
|---|---|
| Variant | hotspot |
| Disease | DIS-HCC |
| ESCAT tier | IV |
| Evidence summary | PIK3CA in HCC — no targeted approval; atezolizumab + bevacizumab / lenvatinib per usual algorithm. |
Notes
ESCAT IV.
Used By
No reverse references found in the YAML corpus.